select a format

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Poxviridae Infections-Pipeline Review, H2 2016

Poxviridae Infections-Pipeline Review, H2 2016


  • Products Id :- GMDHC8429IDB
  • |
  • Pages: 96
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Poxviridae Infections-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Poxviridae Infections-Pipeline Review, H2 2016', provides an overview of the Poxviridae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Poxviridae Infections , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxviridae Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Poxviridae Infections

The report reviews pipeline therapeutics for Poxviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Poxviridae Infections therapeutics and enlists all their major and minor projects

The report assesses Poxviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Poxviridae Infections

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Poxviridae Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Poxviridae Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Poxviridae Infections Overview 9

Therapeutics Development 10

Pipeline Products for Poxviridae Infections-Overview 10

Pipeline Products for Poxviridae Infections-Comparative Analysis 11

Poxviridae Infections-Therapeutics under Development by Companies 12

Poxviridae Infections-Therapeutics under Investigation by Universities/Institutes 14

Poxviridae Infections-Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Poxviridae Infections-Products under Development by Companies 17

Poxviridae Infections-Products under Investigation by Universities/Institutes 18

Poxviridae Infections-Companies Involved in Therapeutics Development 19

Bavarian Nordic A/S 19

BioFactura, Inc. 20

CEL-SCI Corporation 21

Chimerix, Inc. 22

China Biologic Products, Inc. 23

CJ HealthCare Corp. 24

EpiVax, Inc. 25

N & N Pharmaceuticals Inc. 26

SIGA Technologies, Inc. 27

Takeda Pharmaceutical Company Limited 28

Tonix Pharmaceuticals Holding Corp. 29

Verrica Pharmaceuticals Inc. 30

Poxviridae Infections-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Combination Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

(plague + small pox) vaccine-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

24a-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BA-368-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

brincidofovir-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

CEL-1000-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

CJ-40011-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

imatinib mesylate-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Monoclonal Antibodies for Infectious Disease-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Monoclonal Antibody for Smallpox-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

nilotinib-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

NN-001-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

PL-801-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

SCV-305-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

Small Molecules for Molluscum Contagiosum-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

small pox vaccine-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

smallpox vaccine-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

smallpox vaccine-Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

tecovirimat-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

varicella hyperimmune globulins-Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

VIR-001-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

VIR-002-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

VP-100-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Poxviridae Infections-Dormant Projects 83

Poxviridae Infections-Discontinued Products 86

Poxviridae Infections-Product Development Milestones 87

Featured News & Press Releases 87

Jun 15, 2016: Bavarian Nordic Announces Expansion of IMVAMUNE Orders from Canadian Government 87

Apr 25, 2016: SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat 87

Mar 17, 2016: SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX 87

Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 88

Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA's Tecovirimat Antiviral 88

Feb 08, 2016: Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 88

Dec 24, 2015: Delaware Supreme Court Affirms Chancery Court Ruling in Favor of PharmAthene 89

Sep 14, 2015: Chimerix and BARDA Announce Contract Extension of USD 13.0 Million for the Continued Development of Brincidofovir for Smallpox 89

Jul 23, 2015: Chimerix Announces Positive Topline Results From Brincidofovir Pivotal Study in Animal Model for Smallpox 90

Jul 07, 2015: Bavarian Nordic Receives Order for IMVAMUNE Smallpox Vaccine from the U.S. Government Valued at USD 133 Million 90

May 13, 2015: Bavarian Nordic Announces Positive Results from Two Pivotal Clinical Studies of IMVAMUNE Smallpox Vaccine 91

Jan 16, 2015: SIGA Technologies Appeals Judgment of Delaware Court of Chancery 92

Jan 07, 2015: Delaware Court of Chancery Issues Order Specifying Amount Of Lump Sum Expectation Damages Payable To PharmAthene; Total Award When Finalized, Including Pre-Judgment Interest, Attorneys' And Expert Witness Fees, Estimated To Be In Excess Of USD 190 Million 92

Dec 23, 2014: Chimerix Provides Recap of 2014 Events 93

Oct 04, 2014: Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE Smallpox Vaccine 94

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Figures

Number of Products under Development for Poxviridae Infections, H2 2016 10

Number of Products under Development for Poxviridae Infections-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy Products, H2 2016 31

Number of Products by Targets, H2 2016 33

Number of Products by Stage and Targets, H2 2016 33

Number of Products by Mechanism of Actions, H2 2016 35

Number of Products by Stage and Mechanism of Actions, H2 2016 35

Number of Products by Routes of Administration, H2 2016 37

Number of Products by Stage and Routes of Administration, H2 2016 37

Number of Products by Top 10 Molecule Types, H2 2016 39

Number of Products by Stage and Top 10 Molecule Types, H2 2016 39

List of Tables

Number of Products under Development for Poxviridae Infections, H2 2016 10

Number of Products under Development for Poxviridae Infections-Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Development, H2 2016 16

Products under Development by Companies, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Poxviridae Infections-Pipeline by Bavarian Nordic A/S, H2 2016 19

Poxviridae Infections-Pipeline by BioFactura, Inc., H2 2016 20

Poxviridae Infections-Pipeline by CEL-SCI Corporation, H2 2016 21

Poxviridae Infections-Pipeline by Chimerix, Inc., H2 2016 22

Poxviridae Infections-Pipeline by China Biologic Products, Inc., H2 2016 23

Poxviridae Infections-Pipeline by CJ HealthCare Corp., H2 2016 24

Poxviridae Infections-Pipeline by EpiVax, Inc., H2 2016 25

Poxviridae Infections-Pipeline by N & N Pharmaceuticals Inc., H2 2016 26

Poxviridae Infections-Pipeline by SIGA Technologies, Inc., H2 2016 27

Poxviridae Infections-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 28

Poxviridae Infections-Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016 29

Poxviridae Infections-Pipeline by Verrica Pharmaceuticals Inc., H2 2016 30

Assessment by Monotherapy Products, H2 2016 31

Assessment by Combination Products, H2 2016 32

Number of Products by Stage and Target, H2 2016 34

Number of Products by Stage and Mechanism of Action, H2 2016 36

Number of Products by Stage and Route of Administration, H2 2016 38

Number of Products by Stage and Molecule Type, H2 2016 40

Poxviridae Infections-Dormant Projects, H2 2016 83

Poxviridae Infections-Dormant Projects (Contd..1), H2 2016 84

Poxviridae Infections-Dormant Projects (Contd..2), H2 2016 85

Poxviridae Infections-Discontinued Products, H2 2016 86

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bavarian Nordic A/S

BioFactura, Inc.

CEL-SCI Corporation

Chimerix, Inc.

China Biologic Products, Inc.

CJ HealthCare Corp.

EpiVax, Inc.

N & N Pharmaceuticals Inc.

SIGA Technologies, Inc.

Takeda Pharmaceutical Company Limited

Tonix Pharmaceuticals Holding Corp.

Verrica Pharmaceuticals Inc.

Poxviridae Infections Therapeutic Products under Development, Key Players in Poxviridae Infections Therapeutics, Poxviridae Infections Pipeline Overview, Poxviridae Infections Pipeline, Poxviridae Infections Pipeline Assessment


Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com